Catalyst Pharmaceutical Partners, Inc announced today that it has begun a clinical trial for a drug called CPP-109, intended for use in the treatment of cocaine addiction. CPP-109 is an oral treatment that inhibits dopamine release that's typically caused by drugs like cocaine and methamphetamine.

"The Phase II clinical trial is expected to enroll 180 cocaine dependent patients at 10 leading addiction treatment clinical centers in the United States. Patients will be treated for a period of 12 weeks, with an additional 12 week follow-up."

Catalyst will begin enrolling patients in the trial once it gets approval from the Institutional Review Board. It expects to release first results of the trial in the summer of 2008. Read more at News-Medical.net.

Labels: addiction, cocaine, treatment